{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:06:32Z","timestamp":1787616392248,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jpba.2023.115758","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T11:33:31Z","timestamp":1696246411000},"page":"115758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Development and validation of a sensitive LC\u2013MS\/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients"],"prefix":"10.1016","volume":"237","author":[{"given":"Yuru","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7391-0270","authenticated-orcid":false,"given":"Haixi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxing","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3580-9155","authenticated-orcid":false,"given":"Xueding","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jpba.2023.115758_bib1","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.jpba.2023.115758_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3\u20134","key":"10.1016\/j.jpba.2023.115758_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jchromb.2009.11.037","article-title":"Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography\/tandem mass spectrometry","volume":"878","author":"Wiegand","year":"2010","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"22","key":"10.1016\/j.jpba.2023.115758_bib4","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.21.01511","article-title":"Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jpba.2023.115758_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1078-0432.CCR-21-1186","article-title":"Pamiparib monotherapy for patients with germline BRCA1\/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study","volume":"28","author":"Wu","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"32","key":"10.1016\/j.jpba.2023.115758_bib6","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jpba.2023.115758_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.radonc.2017.10.017","article-title":"Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials","volume":"126","author":"de Haan","year":"2018","journal-title":"Radiol. Oncol."},{"issue":"12","key":"10.1016\/j.jpba.2023.115758_bib8","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol."},{"issue":"17","key":"10.1016\/j.jpba.2023.115758_bib9","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1158\/1078-0432.CCR-21-1279","article-title":"Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors","volume":"27","author":"Do","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jpba.2023.115758_bib10","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.jpba.2023.115758_bib11","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jpba.2023.115758_bib12","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2023.115758_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpba.2018.07.017","article-title":"Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS\/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products","volume":"160","author":"Thummar","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115758_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jchromb.2013.09.020","article-title":"Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma","volume":"940","author":"Nijenhuis","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115758_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jchromb.2016.11.020","article-title":"Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine","volume":"1040","author":"van Andel","year":"2017","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"3","key":"10.1016\/j.jpba.2023.115758_bib16","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/bcp.15035","article-title":"A randomized, open-label, two-period crossover bridging study on fuzuloparib capsules of different specifications in healthy Chinese volunteers","volume":"88","author":"Jiang","year":"2022","journal-title":"Br. J. Clin. Pharm."},{"issue":"12","key":"10.1016\/j.jpba.2023.115758_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5478","article-title":"Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors","volume":"36","author":"Jiang","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2023.115758_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121844","article-title":"A simple and fast LC-MS\/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma","volume":"1132","author":"Jolibois","year":"2019","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"21","key":"10.1016\/j.jpba.2023.115758_bib19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jchromb.2011.05.003","article-title":"Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma","volume":"879","author":"Sparidans","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115758_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121925","article-title":"Development and validation of an integrated LC-MS\/MS assay for therapeutic drug monitoring of five PARP-inhibitors","volume":"1138","author":"Bruin","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"8","key":"10.1016\/j.jpba.2023.115758_bib21","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.jpba.2023.115758_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.annonc.2022.02.222","article-title":"The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2\/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Francis","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jpba.2023.115758_bib23","unstructured":"Center for Drug Evaluation and Research (CDER), Center of Veterinary Medicine (CVM), Guidance for Industry: Bioanalytical Method Validation, F.D.A. U.S. Department of Health and Human Services, 2018."},{"issue":"11","key":"10.1016\/j.jpba.2023.115758_bib24","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/clinchem\/hvac135","article-title":"Validation of an LC-MS\/MS method using solid-phase extraction for the quantification of 1-84 parathyroid hormone: toward a candidate reference measurement procedure","volume":"68","author":"Farr\u00e9-Segura","year":"2022","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.jpba.2023.115758_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jpba.2023.115758_bib26","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.jpba.2023.115758_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/17425255.2021.1881480","article-title":"A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers","volume":"17","author":"Wu","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.jpba.2023.115758_bib28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41416-021-01632-2","article-title":"Phase 1A\/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours","volume":"126","author":"Lickliter","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.jpba.2023.115758_bib29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/mas.10008","article-title":"Practical implications of some recent studies in electrospray ionization fundamentals","volume":"20","author":"Cech","year":"2001","journal-title":"Mass Spectrom. Rev."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523005277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523005277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:29:47Z","timestamp":1760002187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523005277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":29,"alternative-id":["S0731708523005277"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115758","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a sensitive LC\u2013MS\/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115758"}}